

PCT/DK 03/00827

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 C12Q1/68 A61K38/48 //C12N9/64 A61K39/395

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

 $\label{eq:minimum documentation searched (classification system followed by classification symbols)} IPC \ 7 \ C12Q \ A61K$ 

	ata base consulted during the international search (name of data			
EPO-In	ternal, MEDLINE, BIOSIS, PAJ, WPI	Data, CHEM ABS Data	·	
c. DOCUM	ENTS CONSIDERED TO BE RELEVANT			
Category °	Citation of document, with indication, where appropriate, of the	e relevant passages	Relevant to claim No.	
x	WO 02 06460 A (THIEL STEFFEN; JENS CHRISTIAN (DK)) 24 January 2002 (2002-01-24) page 2, line 17 -page 5, line page 14 -page 15 page 27, line 15 - line 25 page 33, line 11 -page 37, line abstract	4	1-44	
X Fur	ther documents are listed in the continuation of box C.	X Patent family members are listed	l in annex.	
"A" document defining the general state of the art which is not considered to be of particular relevance  "E" earlier document but published on or after the international filling date  "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)  "O" document referring to an oral disclosure, use, exhibition or other means		or priority date and not in conflict will cited to understand the principle or the invention  "X" document of particular relevance; the cannot be considered novel or cannot involve an inventive step when the defended of the cannot be considered to involve an involve an involve an involve an involve an involve an invents, such combined with one or not ments, such combination being obvinithe art.	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled	
	e actual completion of the international search	Date of mailing of the International se	earch report	
	24 May 2004		1 7. 06. 2004	
Name and mailing address of the ISA  European Patent Office, P.B. 5818 Patentlaan 2  NL - 2280 HV Rijswijk  Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  Fax: (+31-70) 340-3016		Authorized officer  TERESE PERSSON /	Authorized officer  TERESE PERSSON / ELY	



Internation No
PCT/DK 03/00827

(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT				
	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.		
Category °	Citation of document, with indication, where appropriate, or the relevant passages			
X	VORUP-JENSEN T ET AL: "Distinct pathways of mannan-binding lectin (MBL) - and C1-complex autoactivation revealed by reconstitution of MBL with recombinant MBL-associated serine protease-2." JOURNAL OF IMMUNOLOGY (BALTIMORE, MD.: 1950) UNITED STATES 15 AUG 2000, vol. 165, no. 4, 15 August 2000 (2000-08-15), pages 2093-2100, XP002280556 ISSN: 0022-1767 page 2094, column 1, paragraphs 3,4	37,38		
<b>X</b>	ROSSI VERONIQUE ET AL: "Substrate specificities of recombinant mannan-binding lectin-associated serine proteases-1 and -2" JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 276, no. 44, 2 November 2001 (2001-11-02), pages 40880-40887, XP002280557 ISSN: 0021-9258 page 40881, column 1, paragraph 5; figure	23,24,27		
X	PETERSEN STEEN VANG ET AL: "Generation of antibodies towards MASP-1 and MASP-2 using bacterial expression systems" MOLECULAR IMMUNOLOGY, vol. 35, no. 6-7, April 1998 (1998-04), page 409 XP002280558 XVII International Complement Workshop; Rhodes, Greece; October 11-16, 1998 ISSN: 0161-5890 abstract			
X	STOVER C M ET AL: "Two constituents of the initiation complex of the mannan-binding lectin activation pathway of complement are encoded by a single structural gene."  JOURNAL OF IMMUNOLOGY (BALTIMORE, MD.: 1950) UNITED STATES 15 MAR 1999, vol. 162, no. 6, 15 March 1999 (1999-03-15), pages 3481-3490, XP002280559 ISSN: 0022-1767 page 3483, column 7, paragraph 3  -/	33		



Internation Application No
PCT/DK 03/00827

		PCT/DK 03/0082/		
C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT				
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.		
X .	DATABASE ZCAPLUS [Online]  "Genes of antibiotic-synthesizing actinomycetes and their use in analysis of gene expression profiles and gene discovery"  retrieved from STN Database accession no. 2003:724939  XP002280563  see sequence, nucleotides 328-348 abstract & EP 1 262 562 A 4 December 2002 (2002-12-04)	23,24,27		
A	PATENT ABSTRACTS OF JAPAN vol. 2002, no. 09, 4 September 2002 (2002-09-04) & JP 2002 153299 A (SUMIKIN BIOSCIENCE KK;KAWAKAMI MASAYA), 28 May 2002 (2002-05-28) abstract	1-44		
A	THOMAS H C ET AL: "Mutation of gene of mannose-binding protein associated with chronic hepatitis B viral infection." LANCET. ENGLAND 23 NOV 1996, vol. 348, no. 9039, 23 November 1996 (1996-11-23), pages 1417-1419, XP002280560 ISSN: 0140-6736 the whole document	1-44		
P¸X	STENGAARD-PEDERSEN KRISTIAN ET AL: "Inherited deficiency of mannan-binding lectin-associated serine protease 2." NEW ENGLAND JOURNAL OF MEDICINE, vol. 349, no. 6, 7 August 2003 (2003-08-07), pages 554-560, XP002280561 ISSN: 0028-4793 (ISSN print) the whole document	1-44		
P,X	CARLSSON M ET AL: "Cystic fibrosis patients heterozygous for MASP-2 gene mutation have lowered MASP-2 concentration, without relation to clinical findings." MOLECULAR IMMUNOLOGY, vol. 40, no. 2-4, September 2003 (2003-09), page 208 XP002280562 9th European Complement Workshop; Trieste, Italy; September 06-09, 2003 ISSN: 0161-5890 (ISSN print) abstract	1-44		





Box I	Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)
This inte	emational Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. X	Claims Nos.: 44 because they relate to subject matter not required to be searched by this Authority, namely:
	see FURTHER INFORMATION sheet PCT/ISA/210
2. X	Claims Nos.: 23-24,27 (all partly) because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
	see FURTHER INFORMATION sheet PCT/ISA/210
з. 🗌	Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box II	Observations where unity of invention is lacking (Continuation of item 2 of first sheet)
This Inte	ernational Searching Authority found multiple inventions in this international application, as follows:
1	
1.	As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2.	As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.	As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4.	No required additional search fees were timely paid by the applicant. Consequently, this international Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remark	on Protest  The additional search fees were accompanied by the applicant's protest.  No protest accompanied the payment of additional search fees.

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Claims Nos.: 44

Claim 44 relates to methods of treatment of the human or animal body by surgery or by therapy or diagnostic methods practised on the human or animal body (PCT Rule 39.1(iv)). Nevertheless, a search has been executed for this claim. The search has been based on the alleged effects of the compounds or compositions.

Continuation of Box I.2

Claims Nos.: 23-24,27 (all partly)

Present claims 23-24 and 27 relate to an extremely large number of possible isolated oligonucleotides. As the claims are worded, they include any oligonucleotide that comprises a sequence of 10 contiguous nucleotides that are identical to 10 contiguous nucleotides in the DNA sequence encoding the MASP-2 protein having a glycine at position 105. Support within the meaning of Article 6 PCT and disclosure within the meaning of Article 5 PCT is to be found, however, for only a very small proportion of the isolated oligonucleotides. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible.

Consequently, the search has been carried out for those parts of the claims which appear to be supported and disclosed, namely those parts related to such isolated oligonucleotides that have actually been made, i.e. SEQ. ID. NO. 5-8.

Additional claims relating to these claims have been searched with the same limitations.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.



Interna, nal Application No PCT/DK 03/00827

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 0206460 A	24-01-2002	AU 7958601 A CA 2415751 A1 CN 1449440 T WO 0206460 A2 EP 1303591 A2 JP 2004504027 T NO 20030114 A NZ 523900 A US 2004038297 A1	30-01-2002 24-01-2002 15-10-2003 24-01-2002 23-04-2003 12-02-2004 25-02-2003 27-02-2004 26-02-2004
EP 1262562 A	04-12-2002	CA 2384352 A1 EP 1262562 A2 JP 2003284572 A US 2003119018 A1	30-11-2002 04-12-2002 07-10-2003 26-06-2003
JP 2002153299 A	28-05-2002	NONE	